AIDP receives patent for multi-ingredient prebiotic formula
AIDP, Inc. has secured U.S. patent 10,881,675 B2 on Jan. 5, 2021 for the combination of Actazin, a green or gold kiwi extract powder rich in the digestive enzyme actinidin, with PreticX xylooligosaccharide (XOS), a prebiotic.
Photo © Shutterstock.com/jovan vitanovski
AIDP, Inc. (City of Industry, CA) secured U.S. patent 10,881,675 B2 on Jan. 5, 2021 for the combination of Actazin, a green or gold kiwi extract powder rich in the digestive enzyme actinidin, with PreticX xylooligosaccharide (XOS), a prebiotic.
In a recent double-blind, placebo-controlled clinical trial, healthy subjects were randomized into three groups: placebo, 600 mg of Actazin, or 600 mg Actazin plus 1.4 g of 70% PreticX for 28 days. Actazin in combination with PreticX gave significantly improved scores over the other two groups, demonstrating improved bowel regulatory of the participants.
“This patent is a great addition to AIDP’s prebiotic portfolio,” said Jennifer Gu, PhD, vice president of research and development of AIDP, in a press release. “Our research agenda focuses on providing proven results to our customers. Securing this patent ensures our customers have a verified unique product for daily digestive support.”
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
